MGTX (MeiraGTx) Net Financial Result

Official company branding of MeiraGTx Holdings (MGTX)

MeiraGTx Holdings plc (MGTX) revenues rely on the implementation of gene therapy to combat retinal pathologies and neurodegeneration, while the business operates within a safe geopolitical environment. This price chart on GURU.Markets illustrates that profit stands at 0.08. MeiraGTx Holdings plc (MGTX) minimizes external risks through in-house production and by expanding its portfolio of drugs for the treatment of neurological and salivary glands.

MGTX (MeiraGTx PLC) Net Profit history from 07/04/2022 to 11/01/2026

Comprehensive metric breakdowns and analytics for MeiraGTx (MGTX)

- stock value and consensus price forecast:
Market Price MeiraGTx Corp|MGTX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization MeiraGTx Corp|MGTX - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share MeiraGTx|MGTX - Book Capitalization|Market Capitalization to Book Value Ratio meiragtx.com|MGTX - Company Total Assets
- debt and liquidity details:
Debt to Capital Ratio MeiraGTx Holdings plc|MGTX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio MeiraGTx Holdings|MGTX - Company Total Debt|Debt to Book Value Ratio MeiraGTx Corp|MGTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings MeiraGTx|Intermediate Coverage Ratio meiragtx.com
- net income and valuation multiples indicators:
MGTX - Company Net Income
Summary company analysis:MeiraGTx Corp
Original product of meiragtx.com

MeiraGTx Holdings plc (MGTX) develops innovative gene therapy methods by leveraging its own viral vector manufacturing capacities. By analyzing the organization's net financial result, an investor can discern the actual cash flow beyond formal GAAP reports. This metric compares operating income against actual R&D and patent costs. The steady growth of the curve confirms the effectiveness of the commercialization of its developments. Volatility in this indicator signals high risks within the scientific sector.

Key competitors

Company Net Income Tempus AI (TEM)|QGEN (Qiagen N.V.) - Net Profit|ionispharma.com (IONS) - Net Financial Result|Company Net Income Repligen (RGEN)|RNA (Avidity Biosciences Inc) - Final Profit|Net Profit CRSP (CRISPR Therapeutics Corp)|Net Profit GeneDx Corp WGS|Ultragenyx Pharmaceutical - Net Profit|Annual Net Income beamtx.com (BEAM)|SRPT (Sarepta) - Net Income|TWST: Profit After Payment of Taxes|Net Income TXG|Company Profit NTLA (Intellia Corp)|Net Income STOK (Stoke Therapeutics)|BLFS (biolifesolutions.com) - Final Profit|Net Profit WVE (Wave Life Sciences Ltd.)|Final Profit MAZE|SION - Company Net Income|Company Net Income Prime Medicine Bio|Taysha Gene Therapies (TSHA) - Company Net Income|QURE (uniqure.com) - Company Net Income|RGNX (REGENXBIO) - Net Profit|Company Profit SLDB (Solid Biosciences Inc)|Net Profit OCGN|Net Financial Result PacBio Corp|Company Net Income Benitec Biopharma Inc. BNTC|DSGN: Company Profit|Rocket Pharmaceuticals, Inc. - Net Profit|Annual Net Income 4DMT (FDMT)|lexeotx.com (LXEO) - Company Net Income|KRRO - Net Financial Result|Net Income EDIT|SLN: Final Profit|Company Net Income ProQR Therapeutics N.V. (PRQR)|CDXS: Profit After Tax|Company Net Income Sangamo SGMO|Nautilus Biotechnology, Inc. - Company Net Income|Metagenomi, Inc. - Net Profit|Precision BioSciences Inc. (DTIL) - Net Income|generationbio.com (GBIO) - Company Net Income|Net Income Boundless Bio Inc.|XCUR (Exicure Inc.) - Net Profit|IMNN - Annual Net Income|Net Income PHIO (Phio Pharmaceuticals)|Profit After Payment of Taxes MBIO|TransCode Therapeutics, Inc. - Net Income|BNGO: Company Profit|Applied DNA - Net Profit|BLUE (bluebird bio, Inc) - Company Profit|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Net Profit Regulus Therapeutics, Inc.|Company Net Income Syros (SYRS)|Net Income Telesis Bio, Inc TBIO|Net Profit TCON (TRACON Pharmaceuticals)|unitybiotechnology.com (UBX) - Company Net Income